The current case describes epistaxis in a patient treated with a daily regimen of topiramate 100mg for migraine. The patient had not a past medical history of nosebleeds and laboratory parameters were within normal ranges. She was then advised to withdraw topiramate, and the epistaxis resolved within 12 hours after its discontinuation. Since then, the patient never complained other blood clotting disorders. The potential antiplatelet activity of topiramate is discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/157488609789007001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Topiramate-induced acute eosinophilic pneumonia.
BMJ Case Rep
September 2024
AFMC Campus, Pune, Maharashtra, India.
Article Synopsis
- * Investigations showed elevated eosinophil counts and serum IgE levels, leading to a diagnosis of eosinophilic pneumonia after other causes were ruled out.
- * The condition was linked to the medication topiramate, which he started for alcohol withdrawal seizures, and stopping the drug resolved all symptoms and imaging abnormalities.
Topiramate-induced ocular complications: case series.
Rom J Ophthalmol
April 2024
Department of Ophthalmology, Father Muller Medical College, Mangalore, India.
Unlabelled: Several ocular adverse effects have been attributed to Topiramate, a sulfonamide derivative. It can cause problems in the eye such as choroidal effusion syndrome, acute angle closure glaucoma, myopic shift, visual field defects, and Myokymia. If not identified early, it can be vision-threatening.
View Article and Find Full Text PDFDistinctive Optical Coherence Tomography Angiography and Indocyanine Green Angiography Imaging Patterns in Topiramate-Induced Choroidal Effusion.
Retin Cases Brief Rep
December 2023
Vitreous Retina Macula Consultants of New York, New York, NY.
Purpose: To describe novel findings seen on optical coherence tomography angiography (OCTA) and indocyanine green angiography (ICGA) in a young male patient presenting with bilateral topiramate-induced choroidal effusion.
Methods: Retrospective case report. A comprehensive ophthalmic examination was conducted and multimodal imaging techniques, including B-scan ultrasound, OCT, OCTA, and ICGA were analyzed.
Valproate-induced burning mouth syndrome in a male with fibromyalgia and bipolar spectrum disorder.
Arch Clin Cases
September 2023
Department of Psychiatry, Unit of Psychiatric Disorders in Medical Complex Pathologies, University of Pisa, Pisa, Italy.
Burning mouth syndrome is a chronic painful condition characterized by a subjective intraoral pain and burning sensations in the absence of an identifiable medical, dental, or psychiatric cause. Although the underlying etiology is currently unclear, an idiopathic (or primary) form and a secondary form to other conditions are formally recognized. However, as several authors have suggested, it might be of clinical utility to consider the existence of a third clinical entity, namely Drug-Induced Burning mouth syndrome, for its therapeutic implications.
View Article and Find Full Text PDFPresumed topiramate-induced retinopathy in a 58-year-old woman.
Digit J Ophthalmol
October 2023
St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.
Article Synopsis
- - A 58-year-old woman experienced progressive visual loss after taking topiramate for migraines over 3-4 years, reporting issues like light adaptation difficulty and color vision problems.
- - Her visual acuity was severely diminished, and tests such as optical coherence tomography and electroretinogram revealed abnormalities consistent with retinal damage.
- - Extensive medical testing ruled out other potential causes, suggesting that her condition was likely induced by the long-term use of topiramate.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!